

OCT - 5 2000

K002802

SECTION X
SPECIAL 510(K) SUMMARY

Sponsor: Boston Scientific Corporation
One Scientific Place
Natick, MA 01760-1537

Contact Person: Carol J. Holloway
Senior Regulatory Affairs Specialist
Phone: 508-650-8514
Fax: 508-650-8389

Submission Date: 9/7/00

Common/Usual Names: Sphincterotome

Trade/Proprietary Name: Rapid Exchange™ Tapertome

Device Classification and Name: Boston Scientific Corporation believes that the Rapid Exchange Tapertome is classified as Class II.
21CFR § 876.4300
Product Code: KNS

Substantial Equivalence: Boston Scientific Corporation believes that Rapid Exchange™ Tapertome is substantially equivalent to the currently marketed Rapid Exchange™ Sphincterotomes cleared via 510(k) K970053 (Ultratome RX). A comparison of the descriptive characteristics of these products demonstrate the Rapid Exchange™ Tapertome is equivalent in its indications for use, while being very similar in design and identical in materials. In addition, Boston Scientific Corporation has presented validation testing and biocompatibility information. The information presented provides assurance that the Rapid Exchange® Tapertome will meet the minimum requirements that are considered acceptable for its intended use.

Product Testing: The Rapid Exchange™ Tapertome has successfully passed all validation tests used to verify its safety and performance. A biocompatibility assessment was performed on the patient- and fluid-contact materials with satisfactory results.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

OCT - 5 2000

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Carol J. Holloway
Senior Regulatory Affairs Specialist
Microvasive Endoscopy
Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537

Re: K002802
Rapid Exchange™ Tapertome
Dated: September 7, 2000
Received: September 8, 2000
Regulatory Class: II
21 CFR §876.1500/Procode: 78 KNS

Dear Ms. Holloway:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a **classification for your device and** thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Daniel G. Schultz, M.D.
Captain, USPHS
Acting Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure (s)

SECTION I
INDICATIONS FOR USE

K 00 2802

Page 1 of 1

510(k) Number (if known):

Device Name: **Rapid Exchange™ Tapertome**

Indications For Use:

The Rapid Exchange™ Tapertome is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. The Microvasive® Rapid Exchange™ Tapertome can also be used to cannulate and to inject contrast medium.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)


Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(Per 21 CFR 801.109)

or

Over-The-Counter Use _____

(Optional Format 1-2-96)



(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices

510(k) Number K002802